Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 9681-9682 [05-3734]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 38 / Monday, February 28, 2005 / Notices
Dr.
Peter J. Lee, Division of Nuclear
Materials Safety, U.S. Nuclear
Regulatory Commission, Region III,
2443 Warrenville Road, Lisle, Illinois
60532–4352; telephone (630) 829–9870;
or by e-mail at pjl2@nrc.gov.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
I. Introduction
The U.S. Nuclear Regulatory
Commission (NRC) is considering the
issuance of a license amendment to
terminate Material License No. 24–
17152–02 issued to Maxim
Technologies, Inc. (the licensee). The
license amendment will approve the
licensee’s St. Louis, Missouri facility for
unrestricted use.
The NRC staff prepared an
Environmental Assessment in support
of this license action in accordance with
the requirements of Title 10, Code of
Federal Regulations Part 51,
‘‘Environmental Protection Regulations
for Domestic Licensing and Related
Regulatory Functions.’’ Based on the
Environmental Assessment, the NRC
concluded that a Finding of No
Significant Impact is appropriate. The
amendment will be issued following the
publication of this Notice.
II. EA Summary
The purpose of the proposed
amendment is to terminate the
licensee’s byproduct material license
and release its St. Louis, Missouri
facility for unrestricted use. On October
14, 1983, the NRC authorized the
licensee to conduct radiochemical
analysis of environmental samples at
the facility located at 12161 Lackland
Road, St. Louis, Missouri. On April 17,
1989, the NRC authorized the
unrestricted release of the 12161
Lackland Road, St. Louis, Missouri
facility for unrestricted use and
approved the licensee’s current facility
located at 1908 Innerbelt Business
Center Drive, St. Louis, Missouri. On
November 17, 2004, Maxim
Technologies, Inc. submitted a license
amendment requesting termination of
its license and requesting release of its
facility for unrestricted use. The
licensee conducted surveys of the
facility and provided information to the
NRC to demonstrate that the site meets
the license termination criteria in 10
CFR part 20, subpart E, ‘‘Radiological
Criteria for License Termination,’’ for
unrestricted release. The NRC staff
examined the licensee’s request and the
information provided in support of its
request, including the surveys
performed to demonstrate compliance
with 10 CFR 20.1402, ‘‘Radiological
Criteria for Unrestricted Use,’’ to ensure
VerDate jul<14>2003
18:21 Feb 25, 2005
Jkt 205001
that the NRC’s decision is protective of
the public health and safety and the
environment.
III. Finding of No Significant Impact
On the basis of the Environmental
Assessment, NRC concluded that there
are no significant environmental
impacts from the proposed amendment
and determined not to prepare an
environmental impact statement.
IV. Further Information
Documents related to this action,
including the application for
amendment and supporting
documentation, are available
electronically at the NRC’s Electronic
Reading Room at https://www.nrc.gov/
reading-rm/adams.html. From this site,
you can access the NRC’s Agencywide
Document Access and Management
System (ADAMS), which provides text
and image files of NRC’s public
documents. The ADAMS accession
numbers for the documents related to
this notice are: ML043240226 for the
November 17, 2004, amendment
request, and ML050460378 for the
Environmental Assessment summarized
above. If you do not have access to
ADAMS or if there are problems in
accessing the documents located in
ADAMS, contact the NRC’s Public
Document Room (PDR) Reference staff
at 1–800–397–4209, 301–415–4737, or
by e-mail to pdr@nrc.gov.
These documents may also be viewed
electronically on the public computers
located at the NRC’s PDR, O 1 F21, One
White Flint North, 11555 Rockville
Pike, Rockville, MD 20852. The PDR
reproduction contractor will copy
documents for a fee.
Dated at Lisle, Illinois, this 15th day of
February 2005.
For the Nuclear Regulatory Commission.
Jamnes L. Cameron,
Chief, Decommissioning Branch, Division of
Nuclear Materials Safety, Region III.
[FR Doc. 05–3735 Filed 2–25–05; 8:45 am]
BILLING CODE 7590–01–P
NUCLEAR REGULATORY
COMMISSION
Advisory Committee on the Medical
Uses of Isotopes: Meeting Notice
U.S. Nuclear Regulatory
Commission.
ACTION: Notice of meeting.
AGENCY:
SUMMARY: The U.S. Nuclear Regulatory
Commission will convene a meeting of
the Advisory Committee on the Medical
Uses of Isotopes (ACMUI) on April 20
and 21, 2005. A sample of agenda items
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
9681
to be discussed during the public
sessions includes: (1) Status of
Rulemaking: Pt. 35 Training and
Experience; (2) Status and Update:
Redefining Medical Events; (3) Case
Experience in Using I–125 Seeds as
Markers; (4) FDA Radiation Dose Limits
for Human Research Subjects Using
Certain Radiolabeled Drugs, and (5)
Establishing Guidance on Exceeding
Dose Limits for Members of the Public
who would serve as Caregivers to
Persons undergoing
Radiopharmaceutical Therapy. To
review the agenda, see https://
www.nrc.gov/reading-rm/doccollections/acmui/agenda/ or contact
arm@nrc.gov. Furthermore, the ACMUI
will brief the Commission regarding its
activities, on April 20, 2005.
Purpose: Discuss issues related to 10
CFR 35, Medical Use of Byproduct
Material.
Dates and Times for Public Meetings:
April 20, 2005, from 8 a.m. to 5 p.m.;
and April 21, 2005, from 10 a.m. to 5
p.m.
Address for Public Meetings: Bethesda
North Marriott Hotel & Conference
Center, 5701 Marinelli Road, North
Bethesda, MD 20852. The precise room
number where the meeting will be held
will be announced in reader boards
located throughout the hotel.
Date and Time for Closed Session
Meeting: April 21, 2005, from 8 a.m. to
10 a.m. This session will be closed so
that NRC staff can brief the ACMUI on
sensitive information regarding
protective security measures, and so
that the ACMUI can discuss internal
personnel matters.
Address for Closed Session Meeting:
Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852. The precise
room number where the meeting will be
held will be announced in reader boards
located throughout the hotel.
Date and Time for Commission
Briefing: April 20, 2005, from 9:30 a.m.
to 11:30 a.m.
Address for Commission Briefing: U.S.
Nuclear Regulatory Commission, One
White Flint North Building,
Commissioners’ Hearing Room 1G16,
11555 Rockville Pike, Rockville, MD,
20852–2738.
FOR FURTHER INFORMATION CONTACT:
Angela R. McIntosh, telephone (301)
415–5030; e-mail arm@nrc.gov of the
Office of Nuclear Material Safety and
Safeguards, U.S. Nuclear Regulatory
Commission, Washington, DC 20555–
0001.
Conduct of the Meeting
Leon S. Malmud, M.D., will chair the
meeting. Dr. Malmud will conduct the
E:\FR\FM\28FEN1.SGM
28FEN1
9682
Federal Register / Vol. 70, No. 38 / Monday, February 28, 2005 / Notices
meeting in a manner that will facilitate
the orderly conduct of business. The
following procedures apply to public
participation in the meeting:
1. Persons who wish to provide a
written statement should submit a
reproducible copy to Angela R.
McIntosh, U.S. Nuclear Regulatory
Commission, Two White Flint North,
Mail Stop T8F5, 11545 Rockville Pike,
Rockville, MD 20852–2738. Submittals
must be postmarked by April 1, 2005,
and must pertain to the topics on the
agenda for the meeting.
2. Questions from members of the
public will be permitted during the
meeting, at the discretion of the
Chairman.
3. The transcript and written
comments will be available for
inspection on NRC’s Web site (https://
www.nrc.gov) and at the NRC Public
Document Room, 11555 Rockville Pike,
Rockville, MD 20852–2738, telephone
(800) 397–4209, on or about July 20,
2005. This meeting will be held in
accordance with the Atomic Energy Act
of 1954, as amended (primarily Section
161a); the Federal Advisory Committee
Act (5 U.S.C. App); and the
Commission’s regulations in Title 10,
U.S. Code of Federal Regulations, part 7.
4. Attendees are requested to notify
Angela R. McIntosh at (301) 415–5030 of
their planned attendance if special
services, such as for the hearing
impaired, are necessary.
Dated at Rockville, Maryland, this 22nd
day of February, 2005.
For the Nuclear Regulatory Commission.
Andrew L. Bates,
Advisory Committee Management Officer.
[FR Doc. 05–3734 Filed 2–25–05; 8:45 am]
BILLING CODE 7590–01–P
NUCLEAR REGULATORY
COMMISSION
Availability of the Office of Nuclear
Regulatory Research Draft Report
Entitled, ‘‘Station Blackout Risk
Evaluation for Nuclear Power Plants,’’
for Comment
Nuclear Regulatory
Commission.
ACTION: Notice of availability of the
Office of Nuclear Regulatory Research
draft report entitled, ‘‘Station Blackout
Risk Evaluation for Nuclear Power
Plants,’’ and request for public
comment.
AGENCY:
SUMMARY: The Nuclear Regulatory
Commission (NRC) is announcing the
availability of the Office of Nuclear
Regulatory Research draft report
VerDate jul<14>2003
18:21 Feb 25, 2005
Jkt 205001
entitled, ‘‘Station Blackout Risk
Evaluation for Nuclear Power Plants.’’
DATES: Comments on this document
should be submitted by April 15, 2005.
Comments received after that date will
be considered to the extent practicable.
To ensure efficient and complete
comment resolution, comments should
include references to the section, page,
and line numbers of the document to
which the comment applies, if possible.
ADDRESSES: Members of the public are
invited and encouraged to submit
written comments to Michael Lesar,
Chief Rules and Directives Branch,
Office of Administration, Mail Stop T–
6D59, U.S. Nuclear Regulatory
Commission, Washington, DC 20555–
0001. Hand-deliver comments attention
to Michael Lesar, 11545 Rockville Pike,
Rockville, MD, between 7:30 a.m. and
4:15 p.m. on Federal workdays.
Comments may also be sent
electronically to: NRCREP@nrc.gov.
This document is available at the
Agencywide Documents Access and
Management System (ADAMS) Public
Electronic Reading Room on the Internet
at the NRC Web site at https://
www.nrc.gov/reading-rm/adams.html
under Accession No. ML050140399, and
at the NRC Public Document Room,
11555 Rockville Pike, Rockville, MD.
The PDR’s mailing address is USNRC
PDR, Washington, DC 20555; telephone
(301) 415–4737 or (800) 397–4205; fax
(301) 415–3548; e-mail PDR@NRC.GOV.
FOR FURTHER INFORMATION CONTACT: Dale
M. Rasmuson, Division of Risk Analysis
and Applications, Office of Nuclear
Regulatory Research, U.S. Nuclear
Regulatory Commission, Washington,
DC 20555–0001. Telephone: 301–415–
7571, e-mail: dmr@nrc.gov.
SUPPLEMENTARY INFORMATION:
Draft Report Entitled, ‘‘Station Blackout
Risk Evaluation for Nuclear Power
Plants’’
This report is an update of several
previous reports analyzing the risk from
loss of offsite power and subsequent
station blackout events at U.S.
commercial nuclear power plants. The
risk measure used is core damage
frequency. Standardized plant analysis
risk (SPAR) models developed by the
U.S. Nuclear Regulatory Commission,
covering the 103 operating commercial
nuclear power plants, were used to
evaluate the risk. Core damage
frequency results indicating
contributions from station blackout
scenarios and other loss of offsite power
scenarios are presented for each of the
103 plants, along with plant class and
industry averages. In addition, a
comprehensive review of emergency
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
diesel generator performance was
performed to obtain current estimates
for input to the SPAR models. Overall
results indicate that core damage
frequencies for loss of offsite power and
station blackout are lower than previous
estimates. Contributing to this risk
reduction is an improvement in
emergency diesel generator
performance.
The NRC is seeking public comment
in order to receive feedback from the
widest range of parties and to ensure
that all information relevant to
developing this document is available to
the NRC staff. This document is issued
for comment only and is not intended
for interim use. The NRC will review
public comments received on the
document, incorporate suggested
changes as necessary, and issue the final
report for use. The NRC will review
public comments received on the
document, incorporate suggested
changes as necessary, and issue the final
report for use.
Dated at Rockville, Maryland, this 16th day
of February, 2005.
For the Nuclear Regulatory Commission.
Charles E. Ader,
Director, Division of Risk Analysis and
Applications, Office of Nuclear Regulatory
Research.
[FR Doc. 05–3736 Filed 2–25–05; 8:45 am]
BILLING CODE 7590–01–P
SECURITIES AND EXCHANGE
COMMISSION
[Release Nos. IA–2360; File No. S7–30–04]
RIN 3235–AJ25
Registration Under the Advisers Act of
Certain Hedge Fund Advisers
Securities and Exchange
Commission.
ACTION: Notice of OMB approval of
collections of information.
AGENCY:
FOR FURTHER INFORMATION CONTACT:
Vivien Liu, Senior Counsel, Office of
Investment Adviser Regulation, Division
of Investment Management, (202) 551–
6787, at the Securities and Exchange
Commission, 450 Fifth Street, NW,
Washington, DC 20549–0506.
SUPPLEMENTARY INFORMATION: The Office
of Management and Budget has
approved the changes to collection of
information requirements described in
Registration Under the Advisers Act of
Certain Hedge Fund Advisers.1 These
collections are titled ‘‘Form ADV’’
(OMB Control No. 3235–0049); ‘‘Form
1 Investment Advisers Act Rel. No. 2333 (Dec. 2,
2004) [69 FR 72054 (Dec. 10, 2004)].
E:\FR\FM\28FEN1.SGM
28FEN1
]]>Agencies
[Federal Register Volume 70, Number 38 (Monday, February 28, 2005)]
[Notices]
[Pages 9681-9682]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-3734]
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
Advisory Committee on the Medical Uses of Isotopes: Meeting
Notice
AGENCY: U.S. Nuclear Regulatory Commission.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The U.S. Nuclear Regulatory Commission will convene a meeting
of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on
April 20 and 21, 2005. A sample of agenda items to be discussed during
the public sessions includes: (1) Status of Rulemaking: Pt. 35 Training
and Experience; (2) Status and Update: Redefining Medical Events; (3)
Case Experience in Using I-125 Seeds as Markers; (4) FDA Radiation Dose
Limits for Human Research Subjects Using Certain Radiolabeled Drugs,
and (5) Establishing Guidance on Exceeding Dose Limits for Members of
the Public who would serve as Caregivers to Persons undergoing
Radiopharmaceutical Therapy. To review the agenda, see https://
www.nrc.gov/reading-rm/doc-collections/acmui/agenda/ or contact
arm@nrc.gov. Furthermore, the ACMUI will brief the Commission regarding
its activities, on April 20, 2005.
Purpose: Discuss issues related to 10 CFR 35, Medical Use of
Byproduct Material.
Dates and Times for Public Meetings: April 20, 2005, from 8 a.m. to
5 p.m.; and April 21, 2005, from 10 a.m. to 5 p.m.
Address for Public Meetings: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. The
precise room number where the meeting will be held will be announced in
reader boards located throughout the hotel.
Date and Time for Closed Session Meeting: April 21, 2005, from 8
a.m. to 10 a.m. This session will be closed so that NRC staff can brief
the ACMUI on sensitive information regarding protective security
measures, and so that the ACMUI can discuss internal personnel matters.
Address for Closed Session Meeting: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. The
precise room number where the meeting will be held will be announced in
reader boards located throughout the hotel.
Date and Time for Commission Briefing: April 20, 2005, from 9:30
a.m. to 11:30 a.m.
Address for Commission Briefing: U.S. Nuclear Regulatory
Commission, One White Flint North Building, Commissioners' Hearing Room
1G16, 11555 Rockville Pike, Rockville, MD, 20852-2738.
FOR FURTHER INFORMATION CONTACT: Angela R. McIntosh, telephone (301)
415-5030; e-mail arm@nrc.gov of the Office of Nuclear Material Safety
and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC
20555-0001.
Conduct of the Meeting
Leon S. Malmud, M.D., will chair the meeting. Dr. Malmud will
conduct the
[[Page 9682]]
meeting in a manner that will facilitate the orderly conduct of
business. The following procedures apply to public participation in the
meeting:
1. Persons who wish to provide a written statement should submit a
reproducible copy to Angela R. McIntosh, U.S. Nuclear Regulatory
Commission, Two White Flint North, Mail Stop T8F5, 11545 Rockville
Pike, Rockville, MD 20852-2738. Submittals must be postmarked by April
1, 2005, and must pertain to the topics on the agenda for the meeting.
2. Questions from members of the public will be permitted during
the meeting, at the discretion of the Chairman.
3. The transcript and written comments will be available for
inspection on NRC's Web site (https://www.nrc.gov) and at the NRC Public
Document Room, 11555 Rockville Pike, Rockville, MD 20852-2738,
telephone (800) 397-4209, on or about July 20, 2005. This meeting will
be held in accordance with the Atomic Energy Act of 1954, as amended
(primarily Section 161a); the Federal Advisory Committee Act (5 U.S.C.
App); and the Commission's regulations in Title 10, U.S. Code of
Federal Regulations, part 7.
4. Attendees are requested to notify Angela R. McIntosh at (301)
415-5030 of their planned attendance if special services, such as for
the hearing impaired, are necessary.
Dated at Rockville, Maryland, this 22nd day of February, 2005.
For the Nuclear Regulatory Commission.
Andrew L. Bates,
Advisory Committee Management Officer.
[FR Doc. 05-3734 Filed 2-25-05; 8:45 am]
BILLING CODE 7590-01-P
